Skip to content
easybpt
Browse topics

Pharmacology

Erythropoiesis-stimulating agents, intravenous iron and potassium binders in kidney disease

Why CKD causes anaemia (erythropoietin deficiency, hepcidin-driven iron restriction), how ESAs, IV iron preparations and HIF-PH inhibitors work and harm, the Hb ceiling from CHOIR, CREATE and TREAT, and the exchange mechanisms, onset and adverse effects of polystyrene sulfonate, patiromer and sodium zirconium cyclosilicate.

Tier 2Medical sciences concept

Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made

3 questions8 flashcards

At a glance

  • CKD anaemia is normocytic and hypoproliferative: reduced erythropoietin (EPO) from peritubular fibroblasts plus iron restriction from raised hepcidin. Blood loss on dialysis adds absolute iron deficiency.
  • Iron first, then an ESA if Hb is still low. KDIGO 2026 recommends against targeting normal Hb and sets a ceiling of 115 g/L on an ESA.
  • IV iron bypasses hepcidin's block on gut absorption. Preparations differ in dose size, infusion time and the hypophosphataemia of ferric carboxymaltose.

Loading the rest of the note…

Finished reading?

Test yourself on it:3 questions8 flashcards

Sources

Last updated
14 November 2026
What changed
  • 14 November 2026 Turnstile bot check on sign-in and signed-out feedback

Send feedback

Type of feedback

The page you're on and your device type are attached automatically.